Kristien Esser’s Post

Gilead Sciences and Tubulis GmbH have entered into an exclusive option and license agreement to discover and develop an antibody-drug conjugate (ADC) targeting a solid tumor! Through this collaboration, Gilead Sciences will gain access to Tubulis GmbH’ proprietary #Tubutecan and #Alco5 platforms. The two companies will work together to determine the optimal technology to deploy, with Tubulis leading efforts in discovery and early development. The focus will be on designing a #topoisomeraseIinhibitorbasedADC candidate with enhanced biophysical properties and stability to address challenges such as durability and #offtargettoxicity. Gilead Sciences has a strong track record of developing therapies that offer significant advancements in treatment, making them an ideal partner to leverage our technology platforms. This aligns with Gilead’s vision to transform the #ADClandscape. While Tubulis GmbH remains dedicated to advancing our own #clinicaldevelopmentprograms, Gilead Sciences is selectively forming #partnershipswithindustryleaders. Tubulis will lead early-stage research and development activities for the ADC program, while Gilead will take over further development and commercialization if the option is exercised. Detailed news: https://lnkd.in/dyXNEZXd Follow our page for more industry updates: https://lnkd.in/de5zNWmK   Know more about #RASLSSConsulting: https://lnkd.in/d_daJ5Xv #GileadSciences #Tubulis #StrategicPartnerships #Solidtumor #ADCLandscapes #Antibodydrugconjugates #RASLSSConsulting #MarketIntelligence #MarketResearch #CompetitiveIntelligence #StrategySupport #PortfolioOptimization #MarketExpansion #PartnerIdentification

Exciting news from The Wistar Institute Institute on being awarded a $2 million grant from the Josh Shapiro Administration to fund their new Center for Advanced Therapeutics, focusing on early-stage drug discovery, bridging innovation in immunotherapy and vaccine biology to accelerate next-generation therapies and medicines. This milestone underscores Greater Philadelphia's position as a national leader in life sciences, fostering groundbreaking research and development. With institutions like The Wistar Institute at the forefront, our region continues to drive advancements that have a global impact. Read more about this exciting development: The Wistar Institute Press Release: #GoodBizPHL #SelectGreaterPHL

Radiant Therapeutics is thrilled to announce the closing of its $35 million Series A financing. This is an important step forward for Radiant. We’ll be adding key members to our team, and accelerating the advance of our lead clinical candidate, 4-1BB, towards clinical trials. I want to personally thank our supportive investors at the Bill & Melinda Gates Foundation and Amplitude Ventures, who are co-leads of the round. Also the investors at BDC Capital, abrdn., who are new to Radiant; and existing investors at FACIT, Alexandria Venture Investments and TIAP - Toronto Innovation Acceleration Partners.   All of our investors see the potential of the Multabody™ platform, which creates a new class of biologics with an unprecedented combination of multivalency, which results in greater avidity or powerful grip on targets and multi-specificity. Multabodies do things that other existing and developmental antibody treatments can’t do, and that’s why we’re so excited about bringing this powerful new tool to the fight against difficult, heterogeneous diseases.   Finally, the Radiant team has brought extraordinary determination and passion to our mission. This is a day to celebrate before we dig in to the hard work ahead of us as we further develop the Multabody platform. Please read our full press release here: www.radiantbio.com. #Radiant #Multabody #Antibodies #Bio #Biotherapeutics #LifeSciences #Cancer #DrugDiscovery #SeriesA #Financing

𝐆𝐢𝐥𝐞𝐚𝐝 𝐒𝐜𝐢𝐞𝐧𝐜𝐞𝐬 𝐏𝐚𝐫𝐭𝐧𝐞𝐫𝐬 𝐰𝐢𝐭𝐡 𝐓𝐮𝐛𝐮𝐥𝐢𝐬 𝐭𝐨 𝐀𝐝𝐯𝐚𝐧𝐜𝐞 𝐀𝐃𝐂 𝐓𝐡𝐞𝐫𝐚𝐩𝐲 𝐟𝐨𝐫 𝐒𝐨𝐥𝐢𝐝 𝐓𝐮𝐦𝐨𝐫𝐬 Gilead Sciences (Nasdaq: GILD) Gilead Sciences and Tubulis Tubulis GmbH have entered into an exclusive option and license agreement to develop a novel antibody-drug conjugate (ADC) targeting solid tumors. The collaboration will leverage Tubulis' Tubutecan and Alco5 platforms to create a topoisomerase I inhibitor-based ADC with enhanced biophysical properties, addressing challenges like durability and off-target toxicity. Key highlights: Financial terms: $20M upfront payment, $30M option fee, and up to $415M in milestone payments, plus tiered royalties. Collaboration scope: Tubulis leads early R&D; Gilead assumes responsibility for development and commercialization upon option exercise. “We are excited to partner with Tubulis to explore next-generation ADC solutions that enhance therapeutic value and advance our oncology pipeline,” said Flavius Martin, MD Flavius Martin, EVP of Research at Gilead Sciences. “Working with a leader like Gilead aligns with our vision to fundamentally transform the ADC landscape,” added Dominik Schumacher, PhD Dominik Schumacher, CEO of Tubulis. This partnership underscores Gilead's commitment to innovative oncology solutions and Tubulis’ strength in ADC development. #GileadSciences #Tubulis #ADCTherapy #OncologyInnovation #SolidTumorResearch #BiopharmaPartnership

MediLink Therapeutics has officially launched the Phase 3 clinical trial of YL201 (B7-H3 ADC) for nasopharyngeal carcinoma. This significant milestone was marked by a successful investigator meeting held in Guangzhou, signaling the start of this pivotal trial.   At the meeting, Dr. Jiaqiang Cai, Co-Founder and CSO of Medilink Therapeutics, introduced the company's proprietary TMALIN® (Tumor Microenvironment Activable LINker-payload) platform technology. This ADC platform, developed with independent intellectual property rights, features dual-cleavage mechanisms leveraging the tumor microenvironment and intracellular lysosomes. TMALIN® represents a major advancement in antibody-drug conjugate therapeutics, offering enhanced solubility, stability, and tumor tissue targeting for improved efficacy.   #InnovationInOncology #ClinicalTrials #ADC #NasopharyngealCarcinoma #Biotechnology #HealthcareInnovation #QimingPortfolio #QimingHealthcare

🔬 Breaking: $181M Funding Round Signals Major Momentum in ADC Space Novo Holdings, OrbiMed, and Jeito have joined forces in a landmark $181M investment round for an ADC-focused biotech company. TL;DR: • Major funding secured for antibody-drug conjugate development • Led by industry heavyweights Novo Holdings, OrbiMed, and Jeito • Signals growing confidence in ADC technology for precision medicine This investment highlights the surging interest in ADCs, combining antibody targeting with potent therapeutics for enhanced cancer treatment precision. Key Strategic Takeaways: • Consider strategic partnerships in the ADC space • Evaluate opportunities for ADC tech advancement • Monitor regulatory landscape for optimized R&D planning Are you seeing increased ADC activity in your sector? Share your thoughts on this emerging trend in precision oncology. #Biotech #PrecisionMedicine #ADC #CancerTherapy #BiotechInvestment #pharma #biotech #medicinetomarket

📢 We’re pleased to share our Q3 2024 financial results and recent operational progress. Some of the highlights are: 🔹 Strong Financial Position: With a cash balance of $18.5M, Allarity is well-positioned financially. 🔹 Enhanced Leadership: We welcomed Jeremy R. Graff, Ph.D., as President and Chief Development Officer, and Jose Iglesias, M.D., as Consultant Chief Medical Officer. Their expertise is invaluable in steering our lead candidate, stenoparib, toward regulatory and clinical success. 🔹 Stenoparib Milestones: Two patients in our Phase 2 trial for advanced ovarian cancer exceeded one year on treatment, underscoring stenoparib’s potential to provide a durable response for those with few other options. 🔹 European Patent for DRP® Companion Diagnostic: Allarity was granted a European patent for our DRP® technology specific to stenoparib, bolstering our IP strategy in key markets like the EU, U.S., and Asia. Read more in our full release: https://lnkd.in/efTpydwg #CancerTreatment #Stenoparib #PrecisionMedicine #ClinicalTrials #Oncology

This post delves into some frequently asked questions about OmniScreen™ and its unique capabilities in providing compliant, large-scale cell line screening solutions that are not only cutting-edge but also aligned with industry standards and regulations. Whether you're a researcher, a biotech professional, or someone keen on understanding the nuances of cell line screening, this discussion will provide valuable insights into how Crown Bioscience can support your scientific endeavors. #Biotech #Oncology

This post delves into some frequently asked questions about OmniScreen™ and its unique capabilities in providing compliant, large-scale cell line screening solutions that are not only cutting-edge but also aligned with industry standards and regulations. Whether you're a researcher, a biotech professional, or someone keen on understanding the nuances of cell line screening, this discussion will provide valuable insights into how Crown Bioscience can support your scientific endeavors. #Biotech #Oncology

SELLAS Life Sciences Group, Inc. Provides Data from Preclinical Studies Suggesting ASXL1 Mutations as Predictor of SLS009 Response in Solid Tumors  #sellas #sls009 #solidtumors #asxl1mutations #biotech